Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015

D E Gilham; J Anderson; J S Bridgeman; Robert E Hawkins; M A Exley; H Stauss; J Maher; M Pule; A K Sewell; G Bendle; S Lee; W Qasim; A Thrasher; E Morris

doi:10.1089/hum.2015.024

Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015

D E Gilham, J Anderson, J S Bridgeman, Robert E Hawkins, M A Exley, H Stauss, J Maher, M Pule, A K Sewell, G Bendle, S Lee, W Qasim, A Thrasher, E Morris

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.

Original language	English
Pages (from-to)	276-85
Number of pages	190
Journal	Hum Gene Ther
Volume	26
Issue number	5
DOIs	https://doi.org/10.1089/hum.2015.024
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/hum.2015.024

http://www.ncbi.nlm.nih.gov/pubmed/25860661

Cite this

Gilham, D. E., Anderson, J., Bridgeman, J. S., Hawkins, R. E., Exley, M. A., Stauss, H., Maher, J., Pule, M., Sewell, A. K., Bendle, G., Lee, S., Qasim, W., Thrasher, A., & Morris, E. (2015). Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Hum Gene Ther, 26(5), 276-85. https://doi.org/10.1089/hum.2015.024

@article{9913ffc15687459a8a1d558cb233a69e,

title = "Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015",

abstract = "Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.",

author = "Gilham, {D E} and J Anderson and Bridgeman, {J S} and Hawkins, {Robert E} and Exley, {M A} and H Stauss and J Maher and M Pule and Sewell, {A K} and G Bendle and S Lee and W Qasim and A Thrasher and E Morris",

note = "Gilham, David Edward Anderson, John Bridgeman, John Stephen Hawkins, Robert Edward Exley, Mark Adrian Stauss, Hans Maher, John Pule, Martin Sewell, Andrew Kelvin Bendle, Gavin Lee, Steven Qasim, Waseem Thrasher, Adrian Morris, Emma eng TS/J003530/1/Medical Research Council/United Kingdom Cancer Research UK/United Kingdom Research Support, Non-U.S. Gov't 2015/04/11 06:00 Hum Gene Ther. 2015 May;26(5):276-85. doi: 10.1089/hum.2015.024.",

year = "2015",

doi = "10.1089/hum.2015.024",

language = "English",

volume = "26",

pages = "276--85",

journal = "Hum Gene Ther",

issn = "1043-0342",

publisher = "Mary Ann Liebert Incorporated",

number = "5",

}

Gilham, DE, Anderson, J, Bridgeman, JS, Hawkins, RE, Exley, MA, Stauss, H, Maher, J, Pule, M, Sewell, AK, Bendle, G, Lee, S, Qasim, W, Thrasher, A & Morris, E 2015, 'Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015', Hum Gene Ther, vol. 26, no. 5, pp. 276-85. https://doi.org/10.1089/hum.2015.024

TY - JOUR

T1 - Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015

AU - Gilham, D E

AU - Anderson, J

AU - Bridgeman, J S

AU - Hawkins, Robert E

AU - Exley, M A

AU - Stauss, H

AU - Maher, J

AU - Pule, M

AU - Sewell, A K

AU - Bendle, G

AU - Lee, S

AU - Qasim, W

AU - Thrasher, A

AU - Morris, E

N1 - Gilham, David Edward Anderson, John Bridgeman, John Stephen Hawkins, Robert Edward Exley, Mark Adrian Stauss, Hans Maher, John Pule, Martin Sewell, Andrew Kelvin Bendle, Gavin Lee, Steven Qasim, Waseem Thrasher, Adrian Morris, Emma eng TS/J003530/1/Medical Research Council/United Kingdom Cancer Research UK/United Kingdom Research Support, Non-U.S. Gov't 2015/04/11 06:00 Hum Gene Ther. 2015 May;26(5):276-85. doi: 10.1089/hum.2015.024.

PY - 2015

Y1 - 2015

N2 - Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.

AB - Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.

U2 - 10.1089/hum.2015.024

DO - 10.1089/hum.2015.024

M3 - Article

SN - 1043-0342

VL - 26

SP - 276

EP - 285

JO - Hum Gene Ther

JF - Hum Gene Ther

IS - 5

ER -

Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this